$Soligenix (SNGX.US)$ shares skyrocketed more than 400% in r...
$Soligenix (SNGX.US)$ shares skyrocketed more than 400% in recent Tuesday trading after the company reported positive results of a study evaluating extended HyBryte treatment in patients with early-stage cutaneous T-cell lymphoma.
The company said six patients were enrolled in the Phase 3 FLASH study and treated with HyBryte over a period of up to 44 weeks, and they responded positively to the therapy with 75% achieving "treatment success."
The company said six patients were enrolled in the Phase 3 FLASH study and treated with HyBryte over a period of up to 44 weeks, and they responded positively to the therapy with 75% achieving "treatment success."
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
